Ionis Pharmaceuticals is paying $45 million upfront for the exclusive right to binders for the delivery of oligonucleotides to tissues expressing TfR1. The deal leaves Bicycle Therapeutics free to license the small molecules for the delivery of all molecular payloads outside of oligonucleotides. Source: Fierce Biotech 13/7/2021